

Cover Story
By Matthew Bin Han Ong
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- How George Tidmarsh crossed the FDA-industry Rubicon
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- Mary Pazdur, 63, Dies of Cancer; What Her Husband Has Learned
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA











